Page 198 - Aet News Today

After another insightful conference this year, these are some of the key legal deal trends to expect from the health care and life sciences industries in 2023.

A contentious debate regarding whether or not nurse practitioners should have more freedom and be less tethered to doctors continues as lawmakers in Pennsylvania spark discussion.

MedCity News is pleased to announce a six-member advisory board that will guide the annual INVEST conference, May 22-24 at the Ritz Carlton Hotel in Chicago.

Ransomware group BlackCat has been targeting healthcare organizations in recent months, and it just went after NextGen Healthcare. Healthcare organizations would be wise to enhance their cybersecurity strategy in defense against BlackCat, as it is “one of the more adaptable ransomware operations in the world,” according to HHS.

The FDA approved TheracosBio’s Brenzavvy as a treatment for type 2 diabetes. But before it won a regulatory nod for controlling blood glucose in adults, it was approved at a different dose (with flavor) as a veterinary product.

Medtech companies should have a team of FDA advisors at the ready to develop and implement pre- and post-market strategies, prevent and resolve pre- or post-market issues and guide lifecycle management

Clinical trial setbacks and financial challenges have led Finch Therapeutics to stop a Phase 3 study for its lead microbiome program, a potential treatment for recurrent C. diff infection. As Finch seeks buyers for its remaining assets, the biotech is laying off most of its staff in a corporate restructuring.

Solving the labor shortage in healthcare requires that organizations come together and try new strategies leveraging their own data to better understand what their teams need.

By following a checklist of considerations to ensure vendors are up to par with regulations and industry standards, you will be protected against any potential future liabilities and ensure that your Personal Health Information is protected.

The Hutchmed drug, fruquintinib, is already approved in China for colorectal cancer. Takeda Pharmaceutical gets global rights to the small molecule, which has started a rolling submission with the FDA and is being readied for regulatory submissions in Europe and Japan.